Abstract:e13538 Background: Currently, with the advances in detection techniques, such as next generation sequencing (NGS), more and more rare or atypical EGFR mutations had been identified. Such as exons 18-25 kinase domain duplications (KDD) and EGFR fusions (EGFR-RAD51 or EGFR-PURB), the importance of EGFR signaling in the pathogenesis of lung cancer and the efficacy of EGFR-TKI treatment had been demonstrated. The aim of this study was to evaluate the prevalence of EGFR fusions in Chinese NSCLC patients, and to study the association between these molecular alterations and clinicopathological characteristics in these patients. Methods: A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2017. A total of 2410 patients with NSCLC (non-squamous/squamous =2061/349) were screened by using next-generation sequencing (NGS)-based 381 genes panel assay for detecting EGFR fusions. Results: Of this entire cohort, just two (0.08%) patients were identified with an EGFR-SEPT14 fusion and an EGFR-RAD51 fusion. These two patients was that a 62-year-old never smoking female, who was diagnosed with lung adenocarcinoma and a 48-year-old male with a 32 pack-year smoking history, who was diagnosed with lung adenocarcinoma. The first patient: EGFR-SEPT14 fusion driven NSCLC responding to icotinib, there were no treatment-related adverse events, including abnormal hepatic, renal function, gastrointestinal reactions, rashes, and cordis damage. Thus far, after several months, the disease is stable and she is continuing treatment with icotinib; The second patient: EGFR-RAD51 fusion driven NSCLC responding to erlotinib will be presented. The patient was considered to have a partial response (PR) to erlotinib. During treatment with erlotinib, no abnormal hepatic and renal function occurred. Conclusions: The frequency of EGFR fusions in Chinese patients with NSCLC is extremely rare (0.08%). The NGS assay provides a novel diagnostic tool. In the future, we can explore differences in the acquired mechanism underlying EGFR TKIs between sensitive EGFR mutations and other uncommon variant NSCLC patients.

P73.01 Clinicopathologic Characteristics and Survival Outcome in East Asian Patients With Non-Small Cell Lung Cancer and FGFR2 Mutations

P70.02 Clinicopathologic Characteristics and Outcomes of East Asian Patients with Non-Small-Cell Lung Cancer and FLT3 Mutations

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

P1.02-058 Molecular Characteristics and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NFE2L2 Mutations

Clinical Significances of FGFR Fusion for the Lung Squamous Cell Carcinoma and Adenocarcinoma

Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

P73.03 A Kinome CRISPR Screen in FGFR-Amplified Lung Cancer

Data from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

EP1.03-24 Clinicopathologic Characteristics and Survival Outcome in Chinese Patients with Non-Small Cell Lung Cancer and HGF Mutations

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

P71.03 A New Combination Therapy for FGFR1-Amplified Lung Cancer

EP1.03-35 Prevalence, Clinicopathologic Characteristics, and Molecular Associations of IGF1R Mutations in East Asian Patients with NSCLC

Supplementary Table 5 and 6 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

P2.03-11 PDGFRA Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

P1.03-32 Molecular Characteristics and Prognosis FBXW7 Mutations in Chinese Non-Small-Cell Lung Cancer Patients

P55.01 Different Types of CDK4 Mutations in East Asian Non-Small Cell Lung Cancer Patients

P70.01 Distribution of CCND1 Mutations in East Asian Patients With Non-Small Cell Lung Cancer

Co-Occurring Alterations Of Erbb2 Exon 20 Insertion In Non-Small Cell Lung Cancer (Nsclc) And The Potential Indicator Of Response To Afatinib

P2.01-45 Clinico-Molecular Characteristics and Prognostic Outcomes of TP53 Mutated Patients with Advanced Non-Small Cell Lung Cancer

P1.02-056 BRAF Non-V600E Mutations Recurrently Found in Non-Small Cell Lung Cancer in Chinese Patients